Powder: -20°C for 3 years | In solvent: -80°C for 1 year
SIAIS100 TFA is a potent BCR-ABL PROTAC degrader, exhibiting a DC50 of 2.7 nM. It is utilized in the research of chronic myeloid leukemia (CML) [1].
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
5 mg | Inquiry | Inquiry | |
50 mg | Inquiry | Inquiry |
Description | SIAIS100 TFA is a potent BCR-ABL PROTAC degrader, exhibiting a DC50 of 2.7 nM. It is utilized in the research of chronic myeloid leukemia (CML) [1]. |
In vitro | SIAIS100 exhibits antiproliferative activity against K562 cells with an IC50 value of 12 nM [1]. It induces degradation of BCR-ABL by 81.78% and 91.20% at concentrations of 5 nM and 100 nM, respectively [1]. SIAIS100 (100 nM; 8 h) significantly decreases BCR-ABL in K562 cells [1]. SIAIS100 (100 nM; 6 h) causes persistent and robust degradation of BCR-ABL, maintaining a durable cellular response post drug removal [1]. Additionally, SIAIS100 (1-1000 nM) significantly reduces mutant G250E/T315I in a dose-dependent manner and inhibits BCR-ABL signaling in 32D cells, as assessed by p-BCR-ABL levels [1]. |
Molecular Weight | 1004.46 |
Formula | C46H51ClF5N9O7S |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
SIAIS100 TFA Angiogenesis Cytoskeletal Signaling Tyrosine Kinase/Adaptors Bcr-Abl inhibitor inhibit